Three biomarkers (HER2, PD-L1, and microsatellite status) in a large cohort of metastatic gastroesophageal adenocarcinomas: The MD Anderson Cancer Center experience

Genitourinary Cancer

PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort

Eur J Cancer

Naffrichoux J, Poupin P, Pouillot W, Linassier C, Rioux-Leclercq N, De Vries-Brilland M, Mourey L, Laguerre B, Oudard S, Gross-Goupil M, Mousset C, Gravis G, Rolland F, Moise L, Emambux S, Vassal C, Zanetta S, Penel N, Albiges L, Fromont G, Cancel M

doi: 10.1016/j.ejca.2024.114121

Lung, Respiratory and Thoracic Cancer

Management of sotorasib-related adverse events and hepatotoxicities following anti-PD-(L)1 therapy: Experience with sotorasib in two French anti-cancer centers and practical guidance proposal

Lung Cancer

Chour A, Basse C, Lebossé F, Bonte PE, Girard N, Duruisseaux M

doi: 10.1016/j.lungcan.2024.107789

Lung, Respiratory and Thoracic Cancer

First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17

Eur J Cancer

Mark M, Froesch P, Gysel K, Rothschild SI, Addeo A, Ackermann CJ, Chiquet S, Schneider M, Ribi K, Maranta AF, Bastian S, von Moos R, Joerger M, Früh M, Swiss Group for Clinical Cancer Research (SAKK)

doi: 10.1016/j.ejca.2024.113600

ASCO 2024

Breast Cancer

DESTINY-Breast06: T-DXd significantly improves PFS in HER2-low and HER2-ultralow metastatic breast cancer

Lung, Respiratory and Thoracic Cancer

Single organ metastatic sites in non-small cell lung cancer: Patient characteristics, treatment patterns and outcomes from a large retrospective Canadian cohort

Lung Cancer

Li Y, Wong M, Zhan L, Corke L, Brown MC, Cheng S, Khan K, Balatnaram K, Chowdhury M, Sabouhanian A, Herman J, Walia P, Strom E, Patel D, García-Pardo M, Schmid S, Eng L, Sacher AG, Leighl N, Bradbury PA, Shepherd FA, Shultz D, Liu G

doi: 10.1016/j.lungcan.2024.107823

ESMO 2024

Breast Cancer

DESTINY-Breast12: T-DXd proved effective in patients with HER2-positive metastatic breast cancer with or without brain metastases

Lung, Respiratory and Thoracic Cancer

Clinical significance of inter-assay discrepancy in PD-L1 evaluation for the efficacy of pembrolizumab in advanced NSCLC with high PD-L1 expression

Lung Cancer

Miyakoshi J, Yoshida T, Kashima J, Shirasawa M, Torasawa M, Matsumoto Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Shiraishi K, Kohno T, Yamamoto N, Yatabe Y, Suzuki T, Ohe Y

doi: 10.1016/j.lungcan.2024.107788

ASCO 2024

Breast Cancer

TROPION-Breast01: PROs data reinforce Dato-DXd as a potential new therapeutic option for HR-positive, HER2-negative metastatic breast cancer

Breast Cancer

TP53-associated early breast cancer: new observations from a large cohort

J Natl Cancer Inst

Sandoval RL, Bottosso M, Tianyu L, Polidorio N, Bychkovsky BL, Verret B, Gennari A, Cahill S, Achatz MI, Caron O, Imbert-Bouteille M, Noguès C, Mawell KN, Fortuno C, Spurdle AB, Tayob N, Andre F, Garber JE

doi: 10.1093/jnci/djae074

Related content

PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort

Management of sotorasib-related adverse events and hepatotoxicities following anti-PD-(L)1 therapy: Experience with sotorasib in two French anti-cancer centers and practical guidance proposal

First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17

DESTINY-Breast06: T-DXd significantly improves PFS in HER2-low and HER2-ultralow metastatic breast cancer

Single organ metastatic sites in non-small cell lung cancer: Patient characteristics, treatment patterns and outcomes from a large retrospective Canadian cohort

DESTINY-Breast12: T-DXd proved effective in patients with HER2-positive metastatic breast cancer with or without brain metastases

Clinical significance of inter-assay discrepancy in PD-L1 evaluation for the efficacy of pembrolizumab in advanced NSCLC with high PD-L1 expression

TROPION-Breast01: PROs data reinforce Dato-DXd as a potential new therapeutic option for HR-positive, HER2-negative metastatic breast cancer

TP53-associated early breast cancer: new observations from a large cohort